Regeneron Pharmaceuticals (REGN) EBITDA (2009 - 2026)
Regeneron Pharmaceuticals (REGN) EBITDA from Jun 30, 2009 to Mar 31, 2026. The TTM Regeneron Pharmaceuticals (REGN) EBITDA is $4.17B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Regeneron Pharmaceuticals (REGN) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -3.64% |
| 3 Years TTM | -4.55% |
| 5 Years TTM | -0.32% |
| 10 Years TTM | +11.69% |
Annual EBITDA change of Regeneron Pharmaceuticals (REGN)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | $766M | -81.41% |
| 2025 | $4.12B | -7.87% |
| 2024 | $4.47B | +0.12% |
| 2023 | $4.47B | -12.05% |
| 2022 | $5.08B | -44.98% |
| 2021 | $9.23B | +142.18% |
| 2020 | $3.81B | +57.53% |
| 2019 | $2.42B | -9.79% |
| 2018 | $2.68B | +20.56% |
| 2017 | $2.23B | +55.02% |
| 2016 | $1.44B | +8.18% |
| 2015 | $1.33B | +51.36% |
| 2014 | $877M | +11.78% |
| 2013 | $784M | +58.55% |
| 2012 | $495M | -384.15% |
| 2011 | -$174M | +123.81% |
| 2010 | -$78M | +29.85% |
| 2009 | -$60M | -20.09% |
| 2008 | -$75M | N/A |
Comparison Regeneron Pharmaceuticals (REGN) five years EBITDA CAGR with competitors
Regeneron Pharmaceuticals (REGN) five years EBITDA CAGR is -0.32%.